Patents Assigned to Melbourne Health
  • Methods and compositions for the treatment of hepatitis B infection
    Patent number: 11773141
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: October 3, 2023
    Assignees: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTH
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • Viral inhibition
    Patent number: 11364256
    Abstract: The technology relates to the use of at least one macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: June 21, 2022
    Assignees: Monash University, Melbourne Health
    Inventors: Kylie Michelle Wagstaff, Leon Caly, David Jans
  • Barley with low levels of hordeins
    Patent number: 11326134
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: May 10, 2022
    Assignees: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, MELBOURNE HEALTH
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • BARLEY WITH LOW LEVELS OF HORDEINS
    Publication number: 20200140793
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Application
    Filed: November 11, 2019
    Publication date: May 7, 2020
    Applicants: Commonwealth Scientific and Industrial Research Organisation, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, MELBOURNE HEALTH
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • Barley with low levels of hordeins
    Patent number: 10501712
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 10, 2019
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Walter and Eliza Hall Institute of Medical Research, Grains Research and Development Corporation, Melbourne Health
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • BARLEY WITH LOW LEVELS OF HORDEINS
    Publication number: 20160130539
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Application
    Filed: September 2, 2015
    Publication date: May 12, 2016
    Applicants: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, MELBOURNE HEALTH
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • Barley with low levels of hordeins
    Patent number: 9133427
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: September 15, 2015
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Walter and Eliza Hall Institute of Medical Research, Grains Research and Development Corporation, Melbourne Health
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • BARLEY WITH LOW LEVELS OF HORDEINS
    Publication number: 20140199434
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Application
    Filed: January 28, 2014
    Publication date: July 17, 2014
    Applicants: GRAINS RESEARCH AND DEVELOPMENT CORPORATION, Walter and Eliza Hall Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, MELBOURNE HEALTH
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • Barley with low levels of hordeins
    Patent number: 8642846
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: February 4, 2014
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Walter and Eliza Hall Institute of Medical Research, Grains Research and Development Corporation, Melbourne Health
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • VIRAL VARIANTS AND METHODS FOR DETECTING SAME
    Publication number: 20130171620
    Abstract: The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.
    Type: Application
    Filed: July 12, 2012
    Publication date: July 4, 2013
    Applicant: MELBOURNE HEALTH
    Inventors: Stephen A. LOCARNINI, Angeline I. Bartholomguez, Thein T. Aye, Robert A. de Man
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 8367317
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: February 5, 2013
    Assignee: Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral variants
    Patent number: 8273527
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: September 25, 2012
    Assignee: Melbourne Health
    Inventors: Angeline Bartholomeusz, Margaret Littlejohn, Anna Ayres, Stephen Locarnini
  • Viral variants with altered susceptibility to nucleoside analogs and uses thereof
    Patent number: 8211633
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: July 3, 2012
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 8211443
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: July 3, 2012
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral variants detection and application
    Patent number: 8008000
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: August 30, 2011
    Assignees: Melbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital Melbourne
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz
  • Viral variants with altered susceptibility to nucleoside analogs and uses thereof
    Patent number: 7989162
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: August 2, 2011
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same
    Patent number: 7931907
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: April 26, 2011
    Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health Service
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 7927601
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other antagonists of HBV DNA polymerase activity and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants. These assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular the resistant HBV variants of the present invention. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: April 19, 2011
    Assignees: Melbourne Health, Fundacion Investigacion y Educacion En Sida
    Inventors: Julie Sheldon, Berta Rodes, Vincent Soriano, Angeline Ingrid Bartholomeusz
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 7887813
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 15, 2011
    Assignees: Melbourne Health, St. Vincent's Hospital Melbourne, Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • HBV variants detection and application
    Patent number: 7875423
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: January 25, 2011
    Assignees: Melbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital Melbourne
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz